L-asparaginase and human malignant disease.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D004342:Drug Hypersensitivity; D004357:Drug Synergism; D004926:Escherichia coli / Q000201:enzymology; D005334:Fever / Q000139:chemically induced; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D066298:In Vitro Techniques; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008025:Ligases / Q000032:analysis; D008213:Lymphocyte Activation / Q000187:drug effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008970:Molecular Weight; D011241:Prednisone / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000378:metabolism; D013237:Stereoisomerism; D014316:Tritium; D014529:Uridine / Q000378:metabolism; D014633:Valine / Q000378:metabolism; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D014316:Tritium; D014750:Vincristine; D001215:Asparaginase; D008025:Ligases; D014633:Valine; D011241:Prednisone; D014529:Uridine